Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337115 | 0.92 | EGFR (0.38) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL19337252 | 0.91 | SIK2 (0.39) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL18387037 | 0.89 | EGFR (0.39) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL19337098 | 0.87 | EGFR (0.41) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL19337257 | 0.86 | PIK3CA (0.41) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL19337176 | 0.86 | EGFR (0.49) | EGFRKDRALK | |
| SCHEMBL20395919 | 0.84 | CFTR (0.35) | EGFRKDRIGF1RALK | |
| SCHEMBL18386752 | 0.83 | EGFR (0.39) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL18387048 | 0.83 | MKNK1 (0.47) | EGFRMKNK2KDRCCNT1CDK9 | |
| SCHEMBL18386961 | 0.83 | KDR (0.39) | EGFRMKNK2KDRCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | EGFR 1/4885MKNK2 4629/4885KDR 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.